开云app官网登录入口网页版-官方正版

#肺癌患者#

303篇内容 | 3955人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1990795, encodeId=62531990e957e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, objectType=article, longId=728258, objectId=3b8ae28258e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b8ae28258e7, replyNumber=0, likeNumber=143, createdTime=2022-08-04, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b8ae28258e7, moduleTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b8ae28258e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990800, encodeId=fde51990800fa, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=王洁/汤富酬/赫捷发现：肺癌患者中，广泛存在混合谱系癌细胞！, objectType=article, longId=735954, objectId=0404e35954e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0404e35954e2, replyNumber=0, likeNumber=179, createdTime=2022-12-29, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0404e35954e2, moduleTitle=王洁/汤富酬/赫捷发现：肺癌患者中，广泛存在混合谱系癌细胞！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0404e35954e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990801, encodeId=7e671990801e4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Cell Genomics：肺腺癌肿瘤内异质性模式与肺癌患者生存率的关系, objectType=article, longId=736932, objectId=030ae369324e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=030ae369324e, replyNumber=0, likeNumber=132, createdTime=2023-03-20, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=030ae369324e, moduleTitle=Cell Genomics：肺腺癌肿瘤内异质性模式与肺癌患者生存率的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=030ae369324e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990802, encodeId=9c89199080209, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, objectType=article, longId=739485, objectId=63fae39485b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63fae39485b1, replyNumber=0, likeNumber=83, createdTime=2023-05-30, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63fae39485b1, moduleTitle=Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63fae39485b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990799, encodeId=70da1990e9926, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, objectType=article, longId=731438, objectId=746ae314385a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746ae314385a, replyNumber=0, likeNumber=96, createdTime=2022-11-29, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746ae314385a, moduleTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=746ae314385a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990793, encodeId=3b681990e9340, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=115, createdTime=2022-12-17, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990797, encodeId=11d31990e9748, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=142, createdTime=2022-09-28, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990796, encodeId=d3ce1990e9617, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, objectType=article, longId=728264, objectId=993de28264a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=993de28264a3, replyNumber=0, likeNumber=93, createdTime=2022-09-18, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=993de28264a3, moduleTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=993de28264a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990788, encodeId=6c981990e8881, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=102, createdTime=2022-09-01, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990798, encodeId=96661990e9804, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, objectType=article, longId=729824, objectId=fd9ae2982470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd9ae2982470, replyNumber=0, likeNumber=109, createdTime=2022-09-23, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd9ae2982470, moduleTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd9ae2982470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990784, encodeId=11201990e840b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=107, createdTime=2022-07-04, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990785, encodeId=ae131990e859b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=91, createdTime=2022-10-01, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990776, encodeId=ae201990e764e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, objectType=article, longId=220981, objectId=37d322098186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d322098186, replyNumber=0, likeNumber=92, createdTime=2022-09-28, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d322098186, moduleTitle=用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37d322098186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990777, encodeId=02051990e77de, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=221034, objectId=5e2522103406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e2522103406, replyNumber=0, likeNumber=105, createdTime=2022-01-21, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e2522103406, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5e2522103406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990794, encodeId=44501990e94a6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响, objectType=article, longId=728259, objectId=88dde28259a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88dde28259a8, replyNumber=0, likeNumber=95, createdTime=2022-07-17, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88dde28259a8, moduleTitle=2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=88dde28259a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990773, encodeId=170a1990e732a, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=肺癌患者空腹血糖特点的回顾性临床研究, objectType=article, longId=220678, objectId=ad9b2206e807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9b2206e807, replyNumber=0, likeNumber=93, createdTime=2022-04-12, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9b2206e807, moduleTitle=肺癌患者空腹血糖特点的回顾性临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad9b2206e807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990787, encodeId=73701990e87e5, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, objectType=article, longId=301654, objectId=d9c830165485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c830165485, replyNumber=0, likeNumber=128, createdTime=2022-03-26, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c830165485, moduleTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9c830165485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990775, encodeId=d1b11990e7597, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=肺癌患者淋巴结转移规律及其相关因素分析, objectType=article, longId=220787, objectId=980c220e8756, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=980c220e8756, replyNumber=0, likeNumber=108, createdTime=2022-04-07, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=980c220e8756, moduleTitle=肺癌患者淋巴结转移规律及其相关因素分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=980c220e8756)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990770, encodeId=42bd1990e70fe, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=从不吸烟与既往吸烟的肺癌患者空气污染暴露情况比较, objectType=article, longId=220409, objectId=ea3d2204094c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea3d2204094c, replyNumber=0, likeNumber=115, createdTime=2022-02-26, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea3d2204094c, moduleTitle=从不吸烟与既往吸烟的肺癌患者空气污染暴露情况比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea3d2204094c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症, objectType=article, longId=294023, objectId=b262294023e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b262294023e9, replyNumber=0, likeNumber=126, createdTime=2022-04-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b262294023e9, moduleTitle=JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b262294023e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

肺癌患者

2020-05-29

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究

2022-08-04

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

王洁/汤富酬/赫捷发现：肺癌患者中，广泛存在混合谱系癌细胞！

2022-12-29

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Cell Genomics：肺腺癌肿瘤内异质性模式与肺癌患者生存率的关系

2023-03-20

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Radiology：术前FDG PET/CT的应用对非小细胞肺癌患者的价值

2023-05-30

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?

2022-11-29

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-12-17

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-09-28

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关

2022-09-18

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-09-01

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！

2022-09-23

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-07-04

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-10-01

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

用吉非替尼对晚期非小细胞肺癌患者进行治疗的效果研究

2022-09-28

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2022-01-21

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响

2022-07-17

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

肺癌患者空腹血糖特点的回顾性临床研究

2022-04-12

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益

2022-03-26

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

肺癌患者淋巴结转移规律及其相关因素分析

2022-04-07

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

从不吸烟与既往吸烟的肺癌患者空气污染暴露情况比较

2022-02-26

仁者大医 (审核中...)

前往app查看评论内容

#肺癌患者#

JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症

2022-04-10

科室
- - 订阅+
  - 更多科室
工具
服务